AzTrials
AzTrials

PROMNCT02524691

Efficacy Study of Rapid Immunoassay Diagnostic Test Utilizing PP12 and AFP, ROM Plus

An observational study of PROM, run by Clinical Innovations, LLC at 3 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study is designed to establish the level of agreement between the ROM Plus test and the diagnosis of ROM as defined by the patient's clinical course, with respect to a population of pregnant women who present to the clinical site with signs and symptoms suggestive of ROM. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
PROM
What is being tested?
Use of Rapid Immunoassay Tests for the Detection of PROM
Type of treatment
Medical device
How many people
324 participants
Where
3 sitesUnited States
Study dates
Aug 2015to Oct 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Pregnant women undergoing an evaluation for suspected ROM.

Who may be able to join

  • Pregnant women >15 weeks gestation undergoing an evaluation for suspected ROM, as indicated by standard site procedures (multiple gestations will not be excluded).
  • Patients (or their legal representatives) who are willing to voluntarily agree to sign a consent form.

Who cannot join

  • Known placental previa
  • Active vaginal bleeding (≥ menstrual period)
  • Individuals < 18 years of age.
  • Patients (or their legal representatives) who are unwilling to voluntarily agree to sign a consent form.

Trial locations and contacts

3 sites in 1 country.

United States3 sites
  • Cooper Health System

    Camden, New Jersey, 08103

  • Christiana Care Health Services

    Newark, Delaware, 19713

  • Intermountain Healthcare

    Salt Lake City, Utah, 84123

Other trials in United States

About this study

The study is designed to establish the level of agreement between the ROM Plus test and the diagnosis of ROM as defined by the patient's clinical course, with respect to a population of pregnant women who present to the clinical site with signs and symptoms suggestive of ROM.

Read the detailed description

Premature rupture of membranes (PROM), defined as spontaneous rupture of membranes (ROM) before the onset of uterine contractions, is one of the most common diagnostic dilemmas in contemporary obstetrical practice. Premature rupture of membranes can occur at any gestational age, and preterm PROM (PPROM, defined as PROM before 37 weeks) is responsible for 20-40% of preterm births. Early and accurate diagnosis of PROM would allow for gestational age-specific obstetrical interventions designed to optimize perinatal outcome and minimize serious complications such as cord prolapse, preterm delivery, fetal distress and infectious morbidity (chorioamnionitis, neonatal sepsis). Conversely, a false-positive diagnosis of PROM may lead to unnecessary obstetric interventions, including hospitalization, administration of antibiotics and corticosteroids, and even induction of labor. Therefore, the correct and timely diagnosis of this disorder is of critical importance to the clinician because PROM and PPROM may be associated with serious maternal and neonatal consequences.

The diagnosis of fetal membrane rupture is conventionally made using a clinical assessment. The most common method of diagnosis includes the sterile speculum exam (SSE) which includes visual inspection of pooling of fluid in the posterior fornix, a nitrazine/pH testing of the vaginal environment, and a microscopic evaluation of the collected specimen (ferning). If during the sterile speculum exam, the clinician observes amniotic fluid leaking from the cervical os, then the diagnosis of rupture can be made without the three additional evaluations. Although the SSE approach is considered an acceptable standard, it requires an intrusive (speculum) examination and may not provide a rapid or accurate diagnosis.

The literature has shown the SSE to have limitations in terms of diagnostic accuracy, cost and technical ease. The test becomes progressively less accurate when more than one hour has elapsed after the membranes are ruptured. The nitrazine assessment, which is the most common method of determining the status of the membranes in hospitals today, has a sensitivity reported between 90-97%, but a specificity as low as 16-70%. The poor specificity is thought to be due to a high rate of false-positives caused by cervicitis, vaginitis, and contamination with blood, urine, semen and antiseptic agents. The reported sensitivity and specificity for the fern test are also less than adequate, at 51% and 70% respectively.

As a result, rapid, point of care, qualitative immunochromatographic tests (ie., ROM Plus®, Amnisure®) have recently gained popularity as aids in the diagnosis of fetal membrane rupture. These tests are designed to detect proteins found in amniotic fluid at high concentrations. One such test, ROM Plus, uses a unique monoclonal/polyclonal antibody approach to detect two different proteins found in amniotic fluid at high concentrations. ROM Plus detects Placental Protein-12 (PP-12, also known as Insulin-like Growth Factor Binding Protein-1) as well as Alpha Fetoprotein (AFP). The combination of PP12 and AFP were chosen not only because of their robust historical literature support as ideal protein markers for amniotic fluid, but also their unique characteristics. PP12 is synthesized by the decidua of the placenta and reaches a very high concentration level in the amniotic fluid early in the first trimester and stays at that level until delivery. AFP is synthesized by the fetal liver and yolk sac and reaches its peak concentration late in the second trimester/early third trimester. This increases the chance that the proteins will be detected, especially in the preterm patients, when the diagnosis of ROM is most crucial. Amnisure uses a monoclonal/monoclonal antibody approach to detect one protein, Placenta-Alpha Microglobulin-1 (PAMG-1).

This study is designed to assess the performance (sensitivity, specificity, PPV, NPV) of ROM Plus and Amnisure as compared to the standard clinical assessment including but not limited to nitrazine, ferning and/or sterile speculum exam confirmed by a thorough chart review after delivery.

Conditions
PROM
Being tested
Use of Rapid Immunoassay Tests for the Detection of PROM

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Use of Rapid Immunoassay Tests for the Detection of PROMDevice

    Also called ROM Plus, Amnisure

    Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The level of agreement between the ROM Plus test and the diagnosis of ROM as defined by the patient's clinical course, with respect to a population of pregnant women who present to the clinical site with signs and symptoms suggestive of ROM

    Measured: 3 months

Secondary outcomes (1)
  1. Number of tests results from the ROM Plus test that provide the same result as the Amnisure test

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Aug 2015 (estimated)
  2. Study startAug 2015
  3. Primary completionMay 2016
  4. Study completionOct 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
324 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02524691
Sponsor's protocol ID
CI-002-RP
Status last verified
Aug 2016
First submitted
31 Jul 2015
Last updated
9 Aug 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of PROM, run by Clinical Innovations, LLC at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The level of agreement between the ROM Plus test and the diagnosis of ROM as defined by the patient's clinical course, with respect to a population of pregnant women who present to the clinical site with signs and symptoms suggestive of ROM (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in